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Background: The purpose of this study was to evaluate the inﬂuence of polymorphism on sleep parameters of
Obstructive Sleep Apnea Syndrome (OSAS) patients.
Methods: Patients were genotyped after a full-night polysomnography using the large Epidemiologic Sleep
Study of São Paulo population-based sample.
Results: Individuals who carry the APOE ε2 allele showed longer sleep latency, lower sleep efﬁciency and
higher numbers of arousals/hour, when compared to ε3 allele homozygous and carriers of ε4 allele (pb0.05).
These ﬁndings remained signiﬁcant even after correction for potential confounders, such as sex, age and
African genetic ancestry.
Conclusion: The APOE polymorphisms may modulate the effects of intermittent hypoxia and sleep
fragmentation in the sleep architecture of OSAS patients, and that the presence of the ε2 allele may serve
as a biological marker for the identiﬁcation of a subgroup of patients who are more likely to suffer with OSAS
detrimental effects on sleep, impacting not only the daily functioning, but also their quality of life.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The majority of sleep disorders are known to be a result of a
complex interaction between environmental factors and individual
genetic susceptibility. Obstructive Sleep Apnea Syndrome (OSAS) is
characterized by repeated episodes of airﬂow reduction (hypopnea)
or cessation (apneas) due to upper airway obstruction during sleep
[1]. These events often generate hypoxemia and alterations in sleep
architecture, such as frequent arousals (sleep fragmentation), reduced
rapid eye movement (REM) sleep and slow wave sleep (stages 3 and
4), as well as consequent daytime somnolence [1]. Since the
identiﬁcation of a candidate region on chromosome 19, including
the Apolipoprotein E (APOE) gene, a number of studies have evaluated
possible associations between polymorphisms in this gene and the
diagnosis of OSAS [2–10].
Human APOE is an apolipoprotein known to act directly in
cholesterol transport and plasma lipoproteinmetabolism [11]. Studies
in mice have demonstrated that, aside from its role on lipid
metabolism, APOE likely has other cellular activities, such as AKT-
transduction signaling related to neuronal protection and survival, as
well as the maintenance of the blood–brain barrier and differential
response to injury by neurotrophic factors in the brain [12]. The most
commonly studied APOE gene polymorphisms are characterized by
amino acid substitutions at positions 112 (rs7412) and 158925, Vila Clementino, SP—zip
55; fax: +55 11 55725092.
).
vier OA license.(rs429358) of the peptide chain, where the most frequent alleles
are ε2 (cysteine-112/cysteine-158—E2 isoform), ε3 (cysteine-112/
arginine-158—E3 isoform), and ε4 (arginine-112/arginine-158—E4
isoform). These two substitutions can generate six genotypes of APOE:
3 homozygous (ε2ε2, ε3ε3, and ε4ε4) and 3 heterozygous (ε2ε3, ε3ε4,
and ε2ε4) [13].
Links between sleep apnea, APOE, and aging disorders related to
mental commitment observed in some dementia patients have been
demonstrated. A more possible explanation of assumed mechanistic
link between sleep apnea and aging effects can be related to dementia
and its potential alterations in hemodynamic property of sleep
disordered breathing on the cerebral circulation [2]. Genetic association
studies evaluating OSAS phenotype and APOE polymorphisms have
produced conﬂicting results [2,4–10,14], with 2 studies showing a
higher risk of OSA in individuals carrying the APOE ε4 allele, one study
reporting a higher risk of OSA in the presence of the APOE ε2 allele, and a
total of ﬁve studies demonstrating no association between OSA and the
APOE alleles. A recent meta-analysis, including the eight studies
mentioned above has suggested that it is unlikely that the APOE
polymorphisms inﬂuence the risk of OSAS itself, since the results do not
support the previous associations between ε4 allele and OSAS [15].
However, the study highlighted promising evidence from previous
studies that these polymorphisms, instead of conferring risk, may
actually be involved in the modulation of the adverse consequences of
sleep-disordered breathing, as demonstrated by studies in human and
animal models, showing an inﬂuence of the APOE gene in neurocogni-
tive dysfunction, brain injury, oxidative stress and inﬂammatory
markers in response to intermittent hypoxia [7,12].
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in comparison with individuals without OSAS, patients with sleep
disorder breathing show an overall increase of sleep stages 1 and 2, and
an important decrease in stages 3, 4, REM sleep and total sleep time,
whichdirectly inﬂuences sleep efﬁciency and is thought to be the causes
of excessive daytime sleepiness and reduced daytime functioning [16].
However, the magnitude of the impact of OSAS on sleep parameters is
highly variable amongpatients, suggesting that genetic factorsmayplay
a role modulating the way individuals cope with the disease
consequences. In this sense, we sought to evaluate if APOE polymor-
phism alleles may exert an effect on the objective sleep quality in
patients with OSAS, as measured by full night polysomnography (PSG),
in a large population-based sample from Sao Paulo, Brazil.
2. Methods
2.1. Studied population
APOE genotypes were examined in individuals participating in the
São Paulo Epidemiologic Sleep Study, a population-based survey, in
which 1042 subjects underwent PSG and were investigated through
sleep questionnaires and blood sample measurements [17]. To obtain
a representative sample of the inhabitants of Sao Paulo, we used a
probabilistic three-stage cluster sampling technique and a sample size
deﬁned to allow for prevalence estimates with 3% precision. Pregnant
and lactating women, people with physical or mental impairments
that prevent self-care, individuals below 20 or over 80 years old, and
people who work every night were not included in the household
drawing. More details regarding sampling procedures can be found in
[17]. The study protocol was approved by the Ethics Committee for
Research of the Universidade Federal de São Paulo (CEP 0593/06) and
registered with ClinicalTrials.gov (number: NCT00596713; name:
Epidemiology of sleep disturbances among adult population of the Sao
Paulo City). Informed consent forms were obtained and signed for all
participants.
2.2. Polysomnography, OSAS assessment and blood samples collection
Individuals were subjected to one full-night PSG at the sleep
laboratory and sleep stages were visually scored by four trained
technicians according to standardized criteria for investigating sleep
[18]. Diagnosis of OSAS was performed according to the International
Classiﬁcation of Sleep Disorders (ICSD-2) [19]. Individuals with OSAS
were considered positive when their Apnea-hypopnoea index (AHI)
was between 5 and 14.9 together with at least one of the following
complaints: loud snoring, daytime sleepiness, fatigue, and breathing
interruptions observed during sleep. Subjects with an AHI equal to or
higher than 15 were also considered having OSAS, regardless of
whether they had any of the aforementioned complaints.
In the day after the PSG, blood samples were collected for lipid
serum levels measurements (total cholesterol, LDL, HDL, VLDL-
cholesterol and triglycerides) and DNA extraction for polymorphism
genotyping. A detailed version with further information about the
methodology has been previously published elsewhere [17].
2.3. APOE and ancestry-informative markers genotyping
DNA was extracted from peripheral whole blood using a standard
protocol [20]. The genotyping of all single nucleotide polymorphisms
(SNPs) selected for this study was performed using allele-speciﬁc
polymerase chain reaction with a molecular beacons assay under
contract from Prevention Genetics (Marshﬁeld, WI; http://www.
preventiongenetics.com). The APOE polymorphism was characterized
by the genotyping of two SNPs within APOE gene (rs7412 and
rs429358) and the population stratiﬁcation in the sample was
estimated using a set of 31 ancestry-informative markers from Africa,Europe, and Native America. The number of ancestral populations (K)
in the sample and individual admixture proportions was estimated
using the Bayesian Markov Chain-Monte Carlo method implemented
in the program Structure 2.1[21–23].
2.4. Statistical analysis
Hardy–Weinberg equilibrium was tested by calculating a χ2 with 1
degree of freedom for each polymorphism that composes APOE
polymorphism.Wegrouped individuals regarding theirAPOEgenotypes
as follows: ε2 allele carriers (ε2ε2 and ε2ε3 genotypes), ε3 homozygous
(ε3ε3 genotype) and ε4 allele carriers (ε3ε4 and ε4ε4 genotypes), in
order to verify the association regarding the presence of at least 1
polymorphic allele (ε2 or ε4). This approach was also adopted to
increase the power to detect associations, once it reduces the number of
tested categories and increases the number of observations per
category. The sleep parameters measured by PSG were compared
among the groups using Kruskal–Wallis and Mann–Whitney tests. In
addition, a multivariate general linear model was used to correct for
potential confounders. Spearman correlation analyses were performed
between lipid levels and sleep parameters as well. Statistical analyses
wereperformedusing SPSS 18.0 (Chicago, IL, USA). Results are shownas
mean±standard deviation, and a p value of 0.05 was established as
statistically signiﬁcant.
3. Results
A total of 293 OSAS patients had valid APOE genotyping. APOE
genotypes were in Hardy–Weinberg equilibrium (pN0.05), the
genotype frequencies were 2.0% for ε2ε2 (N=6), 7.5% for ε2ε3
(N=22), 2.7% for ε2ε4 (N=8), 69.6% for ε3ε3 (N=204), 16.7% for
ε3ε4 (N=49) and 1.4% for ε4ε4 (N=4), and the general allele
frequencies were 7.2% for ε2, 81.7% for ε3, and 11.1% for ε4 allele. As ε2
and ε4 alleles are described to have opposite effects, the ε2ε4
genotype was excluded from analyses, and the ﬁnal sample consisted
of 285 individuals. This ﬁnal sample was 56.8% male, with a mean age
of 50.52±13.80 years. More detailed information about socio-
economic status, gender, age, body mass index and OSAS can be
found elsewhere [1].
Concerning the lipid serum levels, carriers of the ε2 allele showed
decreased LDL-cholesterol levels when compared to ε3 homozygous
(mean difference=−13.3 mg/dL; p=0.028) and ε4 carriers (mean
difference=−26 mg/dL; p=0.003). In addition, ε3 homozygous
showed decreased LDL-cholesterol levels when compared to ε4
carriers (mean difference=−12.6 mg/dL; p=0.025).
When objective sleep parameters were compared among geno-
type groups, it was demonstrated that the ε2 allele carriers showed
longer sleep latency inminutes (29.6±25.0 vs. 16.5±22.9 and 13.7±
13.4 for ε3 homozygous [p=0.001] and ε4 allele carriers [p=0.001],
respectively), a lower percentage of sleep efﬁciency (70.3±16.9 vs.
79.7±12.5 [p=0.002] and 80.2±11.2 [p=0.006]) and a higher
index of arousals per hour (29.8±16.0 vs. 21.2±12.5 [p=0.003] and
22.3±16.1 [p=0.011]) when compared to ε3 homozygous and ε4
carriers, respectively. Furthermore, ε2 allele carriers also spent
signiﬁcantly more time awake in minutes (98.9±56.1), showed a
higher percentage of stage 1 (6.0±3.1) and a lower percentage of
stages 3+4 (17.15±8.4) when compared to ε3 homozygous (67.9±
45.2 [p=0.002]; 4.9±3.3[p=0.027], 21.3±8.6 [p=0.016], respec-
tively). In addition, ε4 carriers spentmore time inminutes awake than
ε3 homozygous (71.9±46.6 vs. 67.9±45.2, respectively [p=0.019]).
To account for multiple testing, a Bonferroni correction for pairwise
comparison was applied, and the signiﬁcance level was divided by
three independent tests (ε2 vs. ε3; ε2 vs. ε4 and ε3 vs. ε4), resulting in
α=0.017. In this sense, only the comparison of percentage of stage 1
between ε2 and ε3 allele carriers (p=0.027), as well as the
comparison of time awake between ε2 and ε4 allele carriers
Table 1
Sleep parameters obtained after polysomnographic recordings for Obstructive Sleep Apnea Syndrome patients among the three APOE genotype groups.
Variables APOE alleles groups p⁎
ε2 ε3 ε4
N Mean SD N Mean SD N Mean SD
Sleep latency 28 29.59 25.00 204 16.53 22.88 53 13.68 13.44 0.002a,b
REM latency 28 123.48 78.15 204 106.14 58.22 53 99.69 51.70 NS
Total sleep time 28 309.54 87.39 204 329.64 73.14 53 341.23 59.83 NS
Sleep efﬁciency 28 70.28 16.93 204 79.75 12.50 53 80.24 11.20 0.007a,b
% Stage 1 28 6.05 3.06 204 4.88 3.29 53 5.42 3.34 0.049a
% Stage 2 28 58.72 10.50 204 55.58 9.80 53 56.45 9.18 NS
% Stages 3 and 4 28 17.15 8.42 204 21.26 8.27 53 19.45 8.03 0.039a
% REM Sleep 28 18.08 8.98 204 18.28 6.50 53 18.68 5.33 NS
Time awake 28 98.95 56.08 204 67.89 45.25 53 71.87 46.60 0.008a,b
Arousals/h 28 29.85 16.02 204 21.17 12.49 53 22.32 16.15 0.011a,b
⁎ Kruskal–Wallis test.
a pb0.05, ε2×ε3 pairwise comparisons.
b pb0.05, ε2×ε4 pairwise comparisons.
2225R. Pellegrino et al. / Clinica Chimica Acta 412 (2011) 2223–2227(p=0.019) did not remain signiﬁcant. Table 1 shows the results for all
the measured sleep parameters and Fig. 1 depicts the statistically
signiﬁcant results in bar charts. No signiﬁcant differences were found
between ε3 homozygous and ε4 allele carriers concerning the other
sleep parameters (pN0.05; Table 1). Interestingly, in an exploratory
analysis, we have performed the same analyses in a sample of 580
individuals without OSAS and found no statistically signiﬁcant
difference in any of the sleep parameters among the genotypes
(data not shown).
To verify whether potential confounders might inﬂuence the
aforementioned associations, the APOE ε3 homozygous and ε4 allele
carriers were grouped and tested against the ε2 allele carriers in a
multivariate general linear model. Sleep latency, sleep efﬁciency and
an index of arousals/hour were used as dependent variables and sex,
age and African genetic ancestry were used as factors and covariates
in the model. After correction, ε2 allele carriers still showed longer
sleep latency (Mean difference=13.06; 95%CI=4.61 to 21.51;
p=0.003), lower sleep efﬁciency (Mean difference=−8.51; 95%
CI=−13.22 to−3.80; pb0.001) and a higher number of arousals per
hour (Mean difference=7.80; 95%CI=2.52 to 13.08; p=0.004) than
ε3 homozygous/ε4 allele carriers.
We also conducted correlation analyses between the lipid levels and
the signiﬁcant sleep parameters and, interestingly, we found that HDL-c
levels were positively correlated with sleep latency (Spearman's
ρ=0.16; p=0.003) and time awake (Spearman's ρ=0.20; pb0.001)
as well as negatively correlated with sleep efﬁciency (Spearman's ρ=
−0.24; pb0.001). Total cholesterol levels were also positively correlat-
ed with sleep latency (Spearman's ρ=0.13; p=0.020). Although all of
these correlationswereweak, we decided to verify the effect of HDL and
total cholesterol levels on the associations between APOE genotype
groups and the sleepparameters using general linearmodels. Regarding
the effect of the genotype groups on sleep latency, the presence of HDL
and total cholesterol as covariates in the model did not interfere the
association with APOE genotypes (p=0.005). In addition, when both
sleep efﬁciency and time awake were modeled with HDL as covariate,
the effect of the genotype groups also remained signiﬁcant (p=0.001
and p=0.006, respectively). These results suggest that the effects of
APOE genotype groups on studied sleep parameters are independent of
the correlation between lipid levels and these parameters.
4. Discussion
Patients who carry the ε2 allele demonstrated longer sleep latency,
lower sleep efﬁciency and a higher index of arousals per hour, when
compared to ε3 homozygous and individuals carrying the ε4 allele.
Moreover, ε2 allele carriers also spent signiﬁcantly more time awake
and showed a higher percentage of stage 1 and a low percentage ofstages 3+4 compared to ε3 homozygous. The differences in sleep
latency and efﬁciency, as well as in the index of arousals per hour
observed in APOE ε2 allele carriers remained signiﬁcant, even after
correction for potential confounders such as age, sex and African
ancestry and correlated lipid levels. In addition, we veriﬁed the well-
known association between ε2 allele and lower LDL-cholesterol,
suggesting that this sample can estimate correctly the effects of APOE
polymorphism on lipid levels measurements and that it can be
representative for association studies regarding APOE polymorphism.
APOE, especially the polymorphisms contained in the three
common alleles ε2, ε3, and ε4, is one of the most thoroughly studied
genetic polymorphisms in humans [24]. Previous results have
demonstrated a higher risk of developing OSAS in individuals
carrying the ε4 allele [6,8], as well as the ε2 allele [9]; however, the
association between APOE alleles and this sleep disorder is not
completely elucidated, with a series of negative ﬁndings. Agreeing
with our results, recent approaches such asmeta-analysis and knock-
out mice studies indicated that, rather than increasing the vulner-
ability to OSAS themselves, this genetic polymorphism of APOE may
actually be related to the modulation of the adverse effects of OSAS
[12,14,25]. In this study, we evaluated the potential impact of APOE
alleles on the objective sleep parameters, which are highly affected in
individuals with OSAS, and are directly associated with the negative
consequences of OSAS, such as excessive daytime somnolence and
poorer cognitive performance. With the vast majority of the
functional studies available to date evaluating the effect of the ε3
and ε4 alleles only, the mechanisms involved in the modulation of
the ε2 allele's effects on sleep parameters of OSAS patients are
currently unknown. Nevertheless, interestingly, although the ε4
allele has been commonly associated with various adverse health
conditions, as well as a higher susceptibility to Alzheimer's and
cardiovascular diseases [26–29], several negative effects of the ε2
allele have also been observed for a number of disorders such as
inﬂammatory diseases, hyperlipoproteinemia type III, macular
degeneration, tardive dyskinesia and colorectal cancer, suggesting
a plausible mechanism for a context-dependent deleterious effect of
the ε2 and ε4 alleles [29]. Agreeing with this hypothesis, we have
demonstrated in a larger samples including individuals not diag-
nosed with OSAS that the association between APOE polymorphism
and various sleep parameters was not observed, suggesting that the
inﬂuence of this polymorphism is restricted to the hypoxia and/or
sleep fragmentation context of OSAS phenotype. Moreover, sleep
dysfunction and excessive daytime somnolence have long been
recognized as common features in patients with Parkinson disease
(PD) [30]. Although still debatable, results from a meta-analysis
evaluating twenty-two eligible studies suggested that the ε2 allele,
and not ε4, is associatedwith an increased risk of developing PD [31].
Fig. 1. Signiﬁcantly associated sleep parameters between APOE genotypes in the Obstructive Sleep Apnea Syndrome patients. Error Bars represent Standard Error.
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allele, but also the ε2 may indeed exert negative effects on disease-
related phenotypes. Initially recognized as a key determinant in
lipoprotein metabolism, functional studies have shown that, consis-
tent with their protective roles in AD, the E2 and E3 isoforms of the
APOE molecule are also associated with facilitation of neurite
outgrowth and apoptosis inhibition, more efﬁciently than the
APOE4 [32]. Nevertheless, considering the wide expression of APOE
across the body and the variability of the structural and biophysical
properties among the three isoforms [32,33], it is possible that other
neuronal homeostasis or physiological functions associated with the
APOE2 variant may hold the clue for understanding its relationship
with reduced sleep quality in patients with OSAS. In this sense,
further functional studies are necessary before we can conﬁrm the
effect of the ε2 allele on sleep parameters of OSAS patients. In
addition, the apparent lack of agreement between the different
studies evaluating the association between APOE alleles/genotypes
and OSAS is consistent with the idea, already mentioned by Larkin et
al. [9], that other OSAS-related locus near APOE gene and in close
linkage disequilibrium with it exists and it is actually responsible for
the linkage peak on chromosome 19, which ﬁrst gave rise to the
speculation that the APOE gene could be involved in the risk of OSAS.In summary, our results demonstrate an association between the
ε2 allele and reduced sleep quality in patients with OSAS, suggesting
that polymorphisms of APOE and its regulatory region may modulate
the deleterious effects of intermittent hypoxia and sleep fragmenta-
tion in the sleep architecture of OSAS patients. Additionally, the
ﬁndings of the present study support the concept that genetic factors
may help explain the inter-individual phenotypic variations and serve
as a useful biological marker for the identiﬁcation of subgroups of
individuals suffering with OSAS. Clearly, more controlled studies,
involving paired individuals with all genotype groups should be
addressed to elucidate the true effect of APOE polymorphism and
OSAS on sleep measurements and the replication of these ﬁndings in
other populations and study designs is essential for establishing the
function of APOE in the pathophysiology of OSAS.
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